Dowling & Yahnke’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Dowling & Yahnke’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$552K	Buy	+7,900	New	+$585K	0.03%	270
2022 Q1	–	Sell	-1,900	Closed	-$279K	–	391
2021 Q4	$279K	Buy	+1,900	New	+$295K	0.01%	329
2019 Q4	–	Sell	-4,300	Closed	-$335K	–	387
2019 Q3	$335K	Sell	4,300 -1,000	-19%	-$93.9K	0.03%	256
2019 Q2	$546K	Hold	5,300	–	–	0.05%	229
2019 Q1	$388K	Buy	+5,300	New	+$361K	0.04%	217

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dowling & Yahnke's MRTX Position: Q3 2022 in Review

Dowling & Yahnke opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022: 7,900 shares worth $552K. The stake represents 0.03% of the portfolio and ranks #270 among its holdings. This is a return to the name: Dowling & Yahnke previously reported a position in MRTX as recently as Q4 2021.

Dowling & Yahnke first reported a position in MRTX in Q1 2019 and has held it in 5 quarters since. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Dowling & Yahnke held 7,900 shares of Mirati Therapeutics, Inc. Common Stock worth $552K as of Q3 2022.
Mirati Therapeutics, Inc. Common Stock was a new Dowling & Yahnke position in Q3 2022.
Mirati Therapeutics, Inc. Common Stock made up 0.03% of Dowling & Yahnke's portfolio in Q3 2022, its #270 holding.
Dowling & Yahnke first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and has held it in 5 quarters since.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.